Natera Wins Patent Litigation Update with 30% Ongoing Royalty
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy NTRA?
Source: Newsfilter
- Court Decision Impact: The U.S. District Court in Delaware ruled on April 6, 2026, that Natera will receive a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales, demonstrating strong judicial support for Natera's patents.
- Patent Validity Confirmation: The jury upheld the validity of all three asserted MRD patents, ensuring damages related to Invitae's MRD products, which further solidifies Natera's innovative position in the precision medicine sector.
- Ongoing Revenue Potential: This ruling not only confirms a 30% ongoing royalty on post-injunction revenues but also maintains the effective royalty of 20.5% on pre-injunction revenues, indicating stable revenue growth prospects for Natera.
- Robust Patent Portfolio: Natera boasts over 650 issued or pending patents, particularly strong in the MRD domain, highlighting its leadership in cell-free DNA and precision medicine.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRA
Wall Street analysts forecast NTRA stock price to rise
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 209.270
Low
205.00
Averages
262.92
High
300.00
Current: 209.270
Low
205.00
Averages
262.92
High
300.00
About NTRA
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Natera Showcases Advances in AI-Driven Genomics at AACR Annual Meeting
- AI-Driven Genomic Analysis: Natera presented a deep learning model for colorectal cancer at the 2026 AACR meeting, trained on data from over 45,000 patients, achieving an AUROC of 0.98, which highlights its potential to transform routine pathology into a scalable genomic profiling platform, thereby accelerating treatment decisions.
- ctDNA Decision Support: A study involving 465 MSI-H metastatic colorectal cancer patients revealed that approximately 40% experienced early ctDNA clearance post-immune checkpoint inhibitor treatment, with Signatera negativity correlating with a 96% three-year overall survival rate, underscoring the technology's significance in cancer treatment.
- Platform Expansion: Natera's tissue-free MRD platform demonstrated strong correlations between ctDNA levels and Signatera quantitative levels across various cancers, with the LatitudeTM assay launched in 2025 and plans for expansion into additional histologies later this year, enhancing its competitive edge.
- Early Cancer Detection: Natera's blood-based screening test showed a sensitivity of 22.5% and specificity of 91.5% for detecting advanced precancerous lesions, covering all histologic subtypes, indicating its potential to redefine early cancer intervention standards.
See More
Natera Wins Patent Dispute, Secures 30% Ongoing Royalty
- Patent Validity Upheld: The U.S. District Court for Delaware confirmed the validity of Natera's three asserted MRD patents, ensuring damages related to Invitae's MRD-related products, which further solidifies Natera's innovative strength in this space.
- Ongoing Royalty Arrangement: The court's ruling establishes a 30% ongoing royalty on certain post-injunction sales, a decision that not only protects Natera's revenue stream but also provides a stable financial outlook for future sales.
- Pre-Injunction Revenue Unchanged: The jury maintained an effective royalty of 20.5% on pre-injunction revenues, indicating Natera's strong position in the patent dispute and ensuring the company's competitiveness in the market.
- Patent Portfolio Advantage: With over 650 issued or pending patents, Natera's robust MRD patent portfolio provides a solid foundation for future growth, particularly in the rapidly evolving oncology testing sector.
See More
Natera Wins Patent Litigation Update with 30% Ongoing Royalty
- Court Decision Impact: The U.S. District Court in Delaware ruled on April 6, 2026, that Natera will receive a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales, demonstrating strong judicial support for Natera's patents.
- Patent Validity Confirmation: The jury upheld the validity of all three asserted MRD patents, ensuring damages related to Invitae's MRD products, which further solidifies Natera's innovative position in the precision medicine sector.
- Ongoing Revenue Potential: This ruling not only confirms a 30% ongoing royalty on post-injunction revenues but also maintains the effective royalty of 20.5% on pre-injunction revenues, indicating stable revenue growth prospects for Natera.
- Robust Patent Portfolio: Natera boasts over 650 issued or pending patents, particularly strong in the MRD domain, highlighting its leadership in cell-free DNA and precision medicine.
See More
Natera's Signatera Study Published in Clinical Cancer Research
- Study Publication: Natera announced that its Signatera study has been published in Clinical Cancer Research, marking the company's ongoing innovation and development in cancer detection.
- Clinical Impact: The publication of this study may enhance the application potential of Signatera in cancer monitoring, thereby strengthening Natera's market position in the biotechnology industry.
- Scientific Recognition: By being published in a reputable journal, Natera's research has gained recognition in the academic community, further validating the effectiveness and reliability of its technology.
- Future Outlook: The release of this study provides Natera with opportunities to expand its market, particularly in the fields of personalized medicine and cancer treatment monitoring.
See More
Signatera Enables Surgery Avoidance for Women Over 70
- Clinical Study Findings: A prospective study published in Clinical Cancer Research reveals that 68% (23/34) of women over 70 tested MRD-negative with Signatera, and none of these patients experienced disease progression, highlighting Signatera's critical role in early breast cancer management.
- Optimized Treatment Choices: All participants in the study opted for primary endocrine therapy (pET) instead of surgery, indicating that Signatera can assist physicians in providing non-surgical treatment options for older patients, thus balancing disease control with quality of life considerations.
- Significant Monitoring Efficacy: Among the 11 patients who were MRD-positive at baseline, 64% (7/11) cleared their circulating tumor DNA (ctDNA) after 6 months, with all remaining free of distant progression, demonstrating Signatera's effectiveness in monitoring treatment response.
- Positive Patient Feedback: Over 80% of patients reported that Signatera informed their treatment decisions without increasing anxiety, further validating the tool's value in managing older breast cancer patients.
See More
Signatera Assay Enhances High-Risk Patient Management
- ASCC Study Findings: A study involving 84 patients with anal squamous cell carcinoma revealed that Signatera testing correlates strongly with clinical outcomes, as patients who were ctDNA-negative at baseline had a 100% one-year overall survival rate, while ctDNA-positive patients had only 63%, highlighting Signatera's role in recurrence risk assessment.
- LARC Patient Selection: Research on 220 locally advanced rectal cancer patients demonstrated that Signatera can identify high-risk relapse patients, with Signatera-positive non-operative management patients being 4.6 times more likely to require surgical intervention, underscoring the importance of personalized treatment strategies.
- Clinical Outcome Comparison: Post-operative, Signatera-negative patients experienced an 11.5% relapse rate compared to 88.0% for positive patients, indicating the significant clinical value of Signatera testing in guiding surgical decisions and monitoring treatment responses.
- Personalized Monitoring Strategies: Natera's Chief Medical Officer stated that early detection of molecular residual disease through Signatera can support more individualized surveillance and treatment decisions, ultimately improving patient survival rates and quality of life.
See More
Natera Showcases Advances in AI-Driven Genomics at AACR Annual Meeting
- AI-Driven Genomic Analysis: Natera presented a deep learning model for colorectal cancer at the 2026 AACR meeting, trained on data from over 45,000 patients, achieving an AUROC of 0.98, which highlights its potential to transform routine pathology into a scalable genomic profiling platform, thereby accelerating treatment decisions.
- ctDNA Decision Support: A study involving 465 MSI-H metastatic colorectal cancer patients revealed that approximately 40% experienced early ctDNA clearance post-immune checkpoint inhibitor treatment, with Signatera negativity correlating with a 96% three-year overall survival rate, underscoring the technology's significance in cancer treatment.
- Platform Expansion: Natera's tissue-free MRD platform demonstrated strong correlations between ctDNA levels and Signatera quantitative levels across various cancers, with the LatitudeTM assay launched in 2025 and plans for expansion into additional histologies later this year, enhancing its competitive edge.
- Early Cancer Detection: Natera's blood-based screening test showed a sensitivity of 22.5% and specificity of 91.5% for detecting advanced precancerous lesions, covering all histologic subtypes, indicating its potential to redefine early cancer intervention standards.
See More
Natera Wins Patent Dispute, Secures 30% Ongoing Royalty
- Patent Validity Upheld: The U.S. District Court for Delaware confirmed the validity of Natera's three asserted MRD patents, ensuring damages related to Invitae's MRD-related products, which further solidifies Natera's innovative strength in this space.
- Ongoing Royalty Arrangement: The court's ruling establishes a 30% ongoing royalty on certain post-injunction sales, a decision that not only protects Natera's revenue stream but also provides a stable financial outlook for future sales.
- Pre-Injunction Revenue Unchanged: The jury maintained an effective royalty of 20.5% on pre-injunction revenues, indicating Natera's strong position in the patent dispute and ensuring the company's competitiveness in the market.
- Patent Portfolio Advantage: With over 650 issued or pending patents, Natera's robust MRD patent portfolio provides a solid foundation for future growth, particularly in the rapidly evolving oncology testing sector.
See More
Natera Wins Patent Litigation Update with 30% Ongoing Royalty
- Court Decision Impact: The U.S. District Court in Delaware ruled on April 6, 2026, that Natera will receive a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales, demonstrating strong judicial support for Natera's patents.
- Patent Validity Confirmation: The jury upheld the validity of all three asserted MRD patents, ensuring damages related to Invitae's MRD products, which further solidifies Natera's innovative position in the precision medicine sector.
- Ongoing Revenue Potential: This ruling not only confirms a 30% ongoing royalty on post-injunction revenues but also maintains the effective royalty of 20.5% on pre-injunction revenues, indicating stable revenue growth prospects for Natera.
- Robust Patent Portfolio: Natera boasts over 650 issued or pending patents, particularly strong in the MRD domain, highlighting its leadership in cell-free DNA and precision medicine.
See More
Natera's Signatera Study Published in Clinical Cancer Research
- Study Publication: Natera announced that its Signatera study has been published in Clinical Cancer Research, marking the company's ongoing innovation and development in cancer detection.
- Clinical Impact: The publication of this study may enhance the application potential of Signatera in cancer monitoring, thereby strengthening Natera's market position in the biotechnology industry.
- Scientific Recognition: By being published in a reputable journal, Natera's research has gained recognition in the academic community, further validating the effectiveness and reliability of its technology.
- Future Outlook: The release of this study provides Natera with opportunities to expand its market, particularly in the fields of personalized medicine and cancer treatment monitoring.
See More
Signatera Enables Surgery Avoidance for Women Over 70
- Clinical Study Findings: A prospective study published in Clinical Cancer Research reveals that 68% (23/34) of women over 70 tested MRD-negative with Signatera, and none of these patients experienced disease progression, highlighting Signatera's critical role in early breast cancer management.
- Optimized Treatment Choices: All participants in the study opted for primary endocrine therapy (pET) instead of surgery, indicating that Signatera can assist physicians in providing non-surgical treatment options for older patients, thus balancing disease control with quality of life considerations.
- Significant Monitoring Efficacy: Among the 11 patients who were MRD-positive at baseline, 64% (7/11) cleared their circulating tumor DNA (ctDNA) after 6 months, with all remaining free of distant progression, demonstrating Signatera's effectiveness in monitoring treatment response.
- Positive Patient Feedback: Over 80% of patients reported that Signatera informed their treatment decisions without increasing anxiety, further validating the tool's value in managing older breast cancer patients.
See More
Signatera Assay Enhances High-Risk Patient Management
- ASCC Study Findings: A study involving 84 patients with anal squamous cell carcinoma revealed that Signatera testing correlates strongly with clinical outcomes, as patients who were ctDNA-negative at baseline had a 100% one-year overall survival rate, while ctDNA-positive patients had only 63%, highlighting Signatera's role in recurrence risk assessment.
- LARC Patient Selection: Research on 220 locally advanced rectal cancer patients demonstrated that Signatera can identify high-risk relapse patients, with Signatera-positive non-operative management patients being 4.6 times more likely to require surgical intervention, underscoring the importance of personalized treatment strategies.
- Clinical Outcome Comparison: Post-operative, Signatera-negative patients experienced an 11.5% relapse rate compared to 88.0% for positive patients, indicating the significant clinical value of Signatera testing in guiding surgical decisions and monitoring treatment responses.
- Personalized Monitoring Strategies: Natera's Chief Medical Officer stated that early detection of molecular residual disease through Signatera can support more individualized surveillance and treatment decisions, ultimately improving patient survival rates and quality of life.
See More
